SG10201912545PA - T cell redirecting bispecific antibodies for the treatment of egfr positive cancers - Google Patents

T cell redirecting bispecific antibodies for the treatment of egfr positive cancers

Info

Publication number
SG10201912545PA
SG10201912545PA SG10201912545PA SG10201912545PA SG10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA SG 10201912545P A SG10201912545P A SG 10201912545PA
Authority
SG
Singapore
Prior art keywords
treatment
bispecific antibodies
positive cancers
egfr positive
cell redirecting
Prior art date
Application number
SG10201912545PA
Other languages
English (en)
Inventor
Rami Lissilaa
Cian Stutz
Stanislas Blein
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of SG10201912545PA publication Critical patent/SG10201912545PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201912545PA 2017-04-24 2018-04-24 T cell redirecting bispecific antibodies for the treatment of egfr positive cancers SG10201912545PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17167709 2017-04-24

Publications (1)

Publication Number Publication Date
SG10201912545PA true SG10201912545PA (en) 2020-02-27

Family

ID=58632245

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909498X SG11201909498XA (en) 2017-04-24 2018-04-24 T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
SG10201912545PA SG10201912545PA (en) 2017-04-24 2018-04-24 T cell redirecting bispecific antibodies for the treatment of egfr positive cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201909498X SG11201909498XA (en) 2017-04-24 2018-04-24 T cell redirecting bispecific antibodies for the treatment of egfr positive cancers

Country Status (11)

Country Link
US (1) US20230159661A1 (es)
EP (1) EP3615571A1 (es)
JP (1) JP2020517659A (es)
KR (1) KR20200002886A (es)
CN (1) CN110831968A (es)
AU (1) AU2018259039A1 (es)
CA (1) CA3060190A1 (es)
EA (1) EA201992143A1 (es)
MX (1) MX2019012606A (es)
SG (2) SG11201909498XA (es)
WO (1) WO2018197502A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603244VA (en) * 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
WO2022178040A1 (en) * 2021-02-16 2022-08-25 City Of Hope Truncated domain iv egfr and uses thereof
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
AU2023245728A1 (en) * 2022-03-30 2024-09-26 Pinetree Therapeutics, Inc. Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
CN114621351B (zh) * 2022-04-27 2023-01-03 华羊生物技术股份有限公司 多特异性抗体及其治疗癌症的用途
WO2024030341A1 (en) * 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US10329350B2 (en) * 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
WO2014131711A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN105189544A (zh) * 2013-04-19 2015-12-23 科瓦根股份公司 具有抗肿瘤活性的新颖的双特异性结合分子
CN104341504B (zh) * 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
SG11201603244VA (en) * 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
CN104774268B (zh) * 2015-01-21 2018-09-28 武汉友芝友生物制药有限公司 一种双特异性抗体egfr×cd3的构建及应用

Also Published As

Publication number Publication date
EP3615571A1 (en) 2020-03-04
KR20200002886A (ko) 2020-01-08
MX2019012606A (es) 2019-12-02
WO2018197502A1 (en) 2018-11-01
CN110831968A (zh) 2020-02-21
EA201992143A1 (ru) 2020-03-13
CA3060190A1 (en) 2018-11-01
SG11201909498XA (en) 2019-11-28
US20230159661A1 (en) 2023-05-25
JP2020517659A (ja) 2020-06-18
AU2018259039A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
HK1245134A1 (zh) 用抗lap單克隆抗體治療癌症
IL279235A (en) DLL3-CD3 bispecific antibodies
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
SG10201912545PA (en) T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
GB201710838D0 (en) Bispecific antibodies
GB201721338D0 (en) Anti-icos Antibodies
IL268479A (en) Anti-PD-1 antibodies for the treatment of lung cancer
IL277861A (en) Antibodies specific to AXL for cancer treatment
ZA202004908B (en) Bispecific antibody
IL274766A (en) Human anti-LIV1 antibodies for the treatment of breast cancer
EP3645040A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
EP3507307A4 (en) BISPECIFIC ANTIBODIES
EP3383497A4 (en) NEW ANTIBODIES FOR THE TREATMENT OF CANCERS
TWI560201B (en) Bi-specific antibodies for treating cancer
SG11202011268VA (en) Monospecific and multispecific anti-tmeff2 antibodies and there uses
IL282355A (en) Bispecific antibodies directed to exosomes
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3
SG11202008513WA (en) De-immunised anti-erbb3 antibodies
EP3728311A4 (en) BIS SPECIFIC HIV-1 NEUTRALIZING ANTIBODIES
IL280421A (en) Cancer treatment by antibody
GB201813138D0 (en) Cancer treatment with an antibody